About
LuminOne builds ARIA, a platform for turning a company's own data and the outside market into real-time commercial insight, and into the work that follows from it. Some of it ships ready to use. A lot of it we build alongside your team.
ARIA is a platform for building commercial workflows in life sciences. The buying-moment work you can try on the home page is one solution running on it. The larger part of what we do is building the specific workflow a team needs, on the same foundation.
Some commercial jobs are common enough to ship as ready-made solutions. Many are not. For those, our team works embedded alongside yours to build a bespoke workflow on the platform, with the same sourcing and approval guarantees, tuned to the problem in front of you.
Underneath both, ARIA reads a company's own systems together with outside signals such as funding, clinical-trial movement, filings, and competitor activity, and turns them into proactive insight a commercial team can act on while it still matters.
Nothing ARIA prepares is sent or written back without someone on your team approving it, every claim is traceable to a primary source, and every action is logged and reversible. In a regulated industry that is not a feature, it is the point.
I spent more than a decade in life-sciences commercial roles, watching the same thing happen. A biotech would raise on Monday, a competitor would call on Tuesday, and my team would hear about it in the next pipeline review. I started LuminOne to close that gap: catch what matters, prepare the work, and leave the judgment with the team.
That conviction is why ARIA keeps a person in the loop on everything it does. In this industry, an AI that invents a fact is a liability, not a rounding error.
Dhruv Patwardhan spent more than a decade in life-sciences commercial roles before founding LuminOne. LuminOne's platform, ARIA, turns a company's own data and outside-market signals into real-time insight and the commercial work that follows, delivered as ready-made solutions or built hands-on with an embedded team for a customer's specific workflows. Nothing it produces goes out until a person approves it. He speaks candidly about where AI earns its place in regulated commercial work, and where it is oversold.
Available to comment on
Also available to consult on
AI strategy, AI deployment, commercial excellence strategy. Independent of ARIA, and not conditional on it. Dhruv has advised other companies on deployment, and takes on this work directly.
Recent appearances
Executive Insights for Life Sciences Innovators, with Don Alexander of GeneCoda
Where AI can genuinely add value for life sciences commercial teams, and what it takes to move past promising pilots to workflows that improve day-to-day execution. Covers source traceability, human judgment, and what leaders should weigh when putting AI into commercial operations.
“It's never the model.”
on why AI projects stall after a pilot
“If you're trying to solve a task, then that is completely non-value added.”
on picking the wrong unit of work
“In this case it's just garbage out at an accelerated rate.”
on what AI does to bad data
Contact & assets
Available for interviews, quotes, and background. Same-day response on deadline.
